Part of The Texas A&M University System
Clinical Trials
124
7 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1871
Active, not recruiting
2
1.6%
Completed
87
70.2%
Enrolling By Invitation
2
1.6%
Not yet recruiting
3
2.4%
Recruiting
21
16.9%
Terminated
3
2.4%
Unknown
3
2.4%
Withdrawn
3
2.4%
No approval data available
- Researchers at Texas A&M University invented Thermostable Raman Interaction Profiling (TRIP), a laser-based technique that directly measures quantum forces governing protein interactions for the first time. - TRIP detects pi-pi stacking, a subtle molecular interaction critical to protein structure and drug binding, by monitoring vibrational shifts in the amino acid phenylalanine. - When tested on the SARS-CoV-2 main protease (Mpro), TRIP accurately predicted antiviral drug potency, with stronger drugs producing more pronounced vibrational signatures. - The technique holds promise for accelerating drug discovery across cancer, Alzheimer's disease, and infectious diseases by enabling direct, real-time assessment of drug-target interactions.
- Chronic heavy alcohol use may speed up biological pathways linked to brain aging and Alzheimer's disease, according to new preclinical research presented at the Research Society on Alcohol annual meeting. - A mouse model study found that acetaldehyde, a toxic alcohol byproduct, reshapes the brain at the molecular level and contributes to Alzheimer's-like pathology, with sex-specific differences observed. - Separate research from Texas A&M University revealed that alcohol affects amyloid-beta and tau pathology in opposite ways within the corticostriatal circuit, challenging assumptions of uniform alcohol effects on Alzheimer's. - Experts caution that these preclinical findings do not prove causation in humans, but they reinforce the importance of discussing alcohol use as a modifiable risk factor for long-term cognitive health.
- Researchers at Texas A&M University developed a two-step treatment using FGF2 and BMP2 growth factors that successfully regenerated bone, joint structures, tendons, and ligaments in mice. - The treatment redirects fibroblast cells away from scar formation toward forming a blastema, a transient cellular structure typically seen in regenerating species like salamanders. - Findings challenge the assumption that mammalian cells are unprogrammable, suggesting regenerative capacity is dormant rather than absent and can be activated without external stem cells. - BMP2 already holds FDA approval for certain applications and FGF2 is in clinical trials, potentially accelerating the path toward human therapeutic applications.
- The CDC's Emerging Infectious Diseases journal published a landmark study in September 2025 officially recognizing Chagas disease as endemic in the United States, not merely an imported infection. - Approximately 300,000 Americans are estimated to be living with Chagas disease, with locally acquired cases confirmed in at least eight states including Texas, California, and Arizona. - The disease, caused by the Trypanosoma cruzi parasite and spread by kissing bugs, can remain silent for decades before causing fatal cardiac complications in 20–30% of chronically infected individuals. - Only eight U.S. states mandate reporting, and two antiparasitic drugs—benznidazole and nifurtimox—are approved for treatment, though physician awareness remains low outside endemic regions.
- The Health Sector Coordinating Council published an 87-page AI governance playbook addressing cybersecurity, privacy, and patient safety risks unique to healthcare AI deployments. - The guide warns that AI hallucinations could lead to wrong diagnoses or drug recommendations, potentially causing patient harm or death, and calls for enterprise-level risk controls. - Healthcare organizations are advised to exclude clinical applications and protected health information from AI indexing features and implement immutable audit logs for HIPAA compliance. - Experts recommend keeping AI inference within organizational networks, involving patients in governance committees, and conducting dedicated HIPAA risk analyses for AI PC capabilities.
- Researchers at Texas A&M University identified rare interneurons from transplanted neural progenitor cells that can reconnect spinal motor circuits and activate leg muscles after injury. - In 20-30% of animal models, graft-derived neurons successfully integrated with spinal motor networks and triggered leg muscle activity when experimentally activated. - The study highlights the importance of activity-based rehabilitation for newly transplanted neurons to adapt and function effectively within damaged spinal circuits. - These findings could advance stem cell therapies for spinal cord injury by identifying specific neuron types that need to be enriched in transplanted cell populations.
- Researchers developed a novel intramuscular injection using self-amplifying RNA to boost production of ANP, a heart-protective hormone, for sustained cardiac repair following myocardial infarction. - In mouse models, the single-dose therapy improved left ventricular ejection fraction from 20% to 40% by day 28, while also reducing fibrosis and infarct size compared to controls. - The treatment demonstrated efficacy across multiple challenging conditions including aged mice, atherosclerosis models, and metabolic syndrome, though earlier intervention proved more effective than delayed treatment. - While promising in animal studies involving mice and pigs, the therapy requires extensive safety testing before clinical translation due to observed inflammatory responses.
- Human Continuum Inc. has appointed Dr. Omar Khalid Sial, Ph.D., as Chief Scientific Officer to lead development of innovative extracellular vesicle topical formulations and advanced biologics. - Dr. Sial brings over 13 years of experience in preclinical research and pharmaceutical drug development, with expertise in neuroscience, immunology, and genetics. - The company is developing a comprehensive platform of exosome-based therapeutics spanning longevity, orthopedics, aesthetics, and dermatology applications. - Human Continuum's lead program features an investigational IV infusion of standardized, cell-free, platelet-derived exosomes designed to modulate systemic inflammation and support cellular health.
- Dr. Simrit Parmar at Texas A&M University has developed an innovative umbilical cord blood-derived T regulatory cell therapy that has demonstrated safety and efficacy in treating over 80 patients with ALS and other inflammatory diseases. - The therapy addresses inflammation using Treg cells that do not require donor-recipient matching and can be manufactured at scale from a single cord blood unit, with products remaining viable for up to three years when frozen. - Recent studies published in NEJM Evidence showed functional improvement in ALS patients following multiple infusions, while a historic partnership with Saudi Arabia's King Faisal Specialist Hospital will launch new clinical trials. - Dr. Parmar aims to secure FDA regulatory approval within two years for aplastic anemia treatment while seeking expanded funding for larger ALS patient studies in the United States.
- Leading pharmacogenomics expert Dr. Sara Rogers highlights PMWC 2025's focus on addressing critical barriers to PGx adoption, including insurance coverage and clinical implementation strategies. - The conference will feature dedicated sessions exploring evidence-based approaches to make pharmacogenomics the standard of care, with emphasis on AI integration and real-world applications. - PMWC 2025 aims to foster collaboration between academia, industry, and healthcare professionals to advance equitable access to precision medicine technologies.
